Washington, D.C. 20549





Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 16, 2019



(Exact name of registrant as specified in its charter)



(State or other jurisdiction of incorporation)


0-29889  94-3248524
(Commission File No.)  (IRS Employer Identification No.)


1180 Veterans Boulevard

South San Francisco, CA

(Address of principal executive offices)



(Zip Code)


Registrant’s telephone number, including area code: (650) 624-1100


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Securities pursuant to Section 12 (b) of the Act:


 Title of Each Class    Trading Symbol(s)    Name of Each Exchange on Which
 Common Stock, par value $0.001 per share    RIGL    The Nasdaq Stock Market LLC







Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2019, Eldon C. Mayer, III informed Rigel Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his position as the Company’s Chief Commercial Officer. Such resignation is expected to be effective as of December 23, 2019.  Rigel’s senior commercial leadership team, all of whom have been with Rigel since prior to the launch of TAVALISSE® (fostamatinib disodium hexahydrate) tablets and played significant roles in establishing the current commercial infrastructure, will report directly to Mr. Rodriguez during this interim period. Rigel has commenced a search for a new chief commercial officer focusing on an experienced leader with a track record of driving market share growth and managing a product in multiple indications. 






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.


Dated: December 17, 2019 RIGEL PHARMACEUTICALS, INC.
By: /s/ Dolly A. Vance
  Dolly A. Vance
  Executive Vice President, General Counsel and Corporate Secretary